6594 POSTER First-line bevacizumab in combination with chemotherapy in the treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): an open-label safety study (MO19390).

MLA

Crinó, L., et al. “6594 POSTER First-Line Bevacizumab in Combination with Chemotherapy in the Treatment of Patients with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer (NSCLC): An Open-Label Safety Study (MO19390).” EJC Supplements, vol. 5, no. 4, Aug. 2007, p. 386. EBSCOhost, https://doi.org/10.1016/S1359-6349(07)71422-2.

APA

Crinó, L., Dansin, E., Garrido Lopez, P., Griesinger, F., Laskin, J., Pavlakis, N., Thatcher, N., Tsai, C. M., Stroyakovskiy, D., & Su, W. C. (2007). 6594 POSTER First-line bevacizumab in combination with chemotherapy in the treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): an open-label safety study (MO19390). EJC Supplements, 5(4), 386. https://doi.org/10.1016/S1359-6349(07)71422-2

Chicago

Crinó, L., E. Dansin, P. Garrido Lopez, F. Griesinger, J. Laskin, N. Pavlakis, N. Thatcher, C.M. Tsai, D. Stroyakovskiy, and W.C. Su. 2007. “6594 POSTER First-Line Bevacizumab in Combination with Chemotherapy in the Treatment of Patients with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer (NSCLC): An Open-Label Safety Study (MO19390).” EJC Supplements 5 (4): 386. doi:10.1016/S1359-6349(07)71422-2.